HK1095090A1 - Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells - Google Patents
Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicellsInfo
- Publication number
- HK1095090A1 HK1095090A1 HK07102024.9A HK07102024A HK1095090A1 HK 1095090 A1 HK1095090 A1 HK 1095090A1 HK 07102024 A HK07102024 A HK 07102024A HK 1095090 A1 HK1095090 A1 HK 1095090A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mammalian cells
- phagocytic
- phagocytic mammalian
- minicells
- gene delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52776403P | 2003-12-09 | 2003-12-09 | |
PCT/IB2004/004406 WO2005056749A2 (en) | 2003-12-09 | 2004-12-08 | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1095090A1 true HK1095090A1 (en) | 2007-04-27 |
Family
ID=34676775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07102024.9A HK1095090A1 (en) | 2003-12-09 | 2007-02-22 | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
Country Status (15)
Country | Link |
---|---|
US (3) | US9169495B2 (zh) |
EP (2) | EP1694361B1 (zh) |
JP (1) | JP4332558B2 (zh) |
CN (2) | CN101954095B (zh) |
AT (1) | ATE501735T1 (zh) |
AU (1) | AU2004297414C1 (zh) |
CA (1) | CA2549840C (zh) |
DE (1) | DE602004031870D1 (zh) |
DK (1) | DK1694361T3 (zh) |
ES (1) | ES2362881T3 (zh) |
HK (1) | HK1095090A1 (zh) |
NZ (1) | NZ547983A (zh) |
PL (1) | PL1694361T3 (zh) |
PT (1) | PT1694361E (zh) |
WO (1) | WO2005056749A2 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1446489E (pt) * | 2001-10-15 | 2012-04-24 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas, como vectores para a transferência de adn e terapia genética in vitro e in vivo |
US7611885B2 (en) * | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
CN101954095B (zh) | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
DK1718338T3 (en) | 2004-02-02 | 2015-08-10 | Engeneic Molecular Delivery Pty Ltd | COMPOSITIONS AND METHODS OF TARGETING IN VITRO AND IN VIVO PHARMACEUTICAL DELIVERY TO BATTERY DIVIDED INTACT MINICELLS |
US8772013B2 (en) * | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
DK2386640T3 (en) * | 2004-08-26 | 2015-04-27 | Engeneic Molecular Delivery Pty Ltd | The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells |
ES2458498T3 (es) | 2006-06-23 | 2014-05-05 | Engeneic Molecular Delivery Pty Ltd. | Administración dirigida de fármacos, ácidos nucleicos terapéuticos y ácidos nucleicos funcionales a célula de mamífero por medio de células bacterianas muertas intactas |
CA2682704C (en) | 2007-03-30 | 2014-07-08 | Engeneic Molecular Delivery Pty. Ltd. | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
EP3020811A1 (en) | 2008-06-25 | 2016-05-18 | Vaxiion Therapeutics, LLC | Regulated genetic suicide mechanism compositions and methods |
DK2675474T3 (en) | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
MX359410B (es) * | 2011-12-13 | 2018-09-27 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. |
WO2014055682A1 (en) | 2012-10-02 | 2014-04-10 | Vaxiion Therapeutics, Inc. | Immunomodulatory minicells and methods of use |
US9017698B2 (en) * | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
TWI737576B (zh) * | 2013-10-04 | 2021-09-01 | 澳大利亞商安珍尼Ic分子輸送私人有限公司 | 使用藥物裝載之雙特異性配位體標靶的微型細胞與干擾素-γ的組合式腫瘤治療 |
US10328159B2 (en) | 2014-10-03 | 2019-06-25 | Engenic Molecular Delivery Pty Ltd. | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
WO2017024059A1 (en) | 2015-08-04 | 2017-02-09 | Vaxiion Therapeutics, Llc | Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use |
WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
US20190328783A1 (en) * | 2016-04-15 | 2019-10-31 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
CA3039010A1 (en) | 2016-10-06 | 2018-04-12 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
WO2018098163A1 (en) | 2016-11-23 | 2018-05-31 | Vaxiion Therapeutics, Llc | Immunomodulatory & oncolytic minicells and methods of use |
AU2019311380A1 (en) | 2018-07-23 | 2021-02-11 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived minicells and methods of using the same |
WO2020222161A1 (en) * | 2019-05-01 | 2020-11-05 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived intact minicells for theranostic applications |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496778A (en) | 1983-10-03 | 1985-01-29 | Exxon Research & Engineering Co. | Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5221479A (en) * | 1991-02-15 | 1993-06-22 | Fuji Photo Film Co., Ltd. | Filtration system |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
NZ288883A (en) | 1994-07-11 | 1998-12-23 | Univ Texas | Conjugates comprising coagulation factors |
WO1998041628A1 (en) | 1997-03-19 | 1998-09-24 | Zymogenetics, Inc. | Secreted salivary zsig32 polypeptides |
US20030004123A1 (en) * | 1997-06-26 | 2003-01-02 | Boucher Richard C. | Targeted gene transfer using G protein coupled receptors |
NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
US6225113B1 (en) | 1998-12-04 | 2001-05-01 | Genvec, Inc. | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus |
BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
WO2002016590A2 (en) | 2000-08-21 | 2002-02-28 | Clonex Development, Inc. | Methods and compositions for increasing protein yield from a cell culture |
US7125679B2 (en) * | 2001-03-07 | 2006-10-24 | Children's Medical Center Corporation | Methods to screen peptide libraries using minicell display |
US7011946B2 (en) * | 2001-05-22 | 2006-03-14 | Trustees Of Tufts College | In vivo assay for identification of antimicrobial agents |
US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US20030194714A1 (en) | 2001-06-05 | 2003-10-16 | Sabbadini Roger A. | Minicell-based transformation |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
PT1446489E (pt) | 2001-10-15 | 2012-04-24 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas, como vectores para a transferência de adn e terapia genética in vitro e in vivo |
EP2272946B9 (en) * | 2002-02-25 | 2015-06-24 | Vaxiion Therapeutics, LLC | Minicell compositions and methods |
US20030203481A1 (en) * | 2002-02-25 | 2003-10-30 | Surber Mark W. | Conjugated minicells |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
CN101954095B (zh) | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
DK2386640T3 (en) | 2004-08-26 | 2015-04-27 | Engeneic Molecular Delivery Pty Ltd | The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells |
DE602005023345D1 (de) | 2004-12-17 | 2010-10-14 | Beth Israel Hospital | Zusammensetzungen für bakteriell vermitteltes gen-silencing sowie verfahren zur verwendung davon |
ES2458498T3 (es) | 2006-06-23 | 2014-05-05 | Engeneic Molecular Delivery Pty Ltd. | Administración dirigida de fármacos, ácidos nucleicos terapéuticos y ácidos nucleicos funcionales a célula de mamífero por medio de células bacterianas muertas intactas |
-
2004
- 2004-12-08 CN CN2010105034256A patent/CN101954095B/zh active Active
- 2004-12-08 PT PT04806560T patent/PT1694361E/pt unknown
- 2004-12-08 WO PCT/IB2004/004406 patent/WO2005056749A2/en active Application Filing
- 2004-12-08 EP EP04806560A patent/EP1694361B1/en not_active Not-in-force
- 2004-12-08 US US10/581,990 patent/US9169495B2/en active Active
- 2004-12-08 ES ES04806560T patent/ES2362881T3/es active Active
- 2004-12-08 CA CA2549840A patent/CA2549840C/en not_active Expired - Fee Related
- 2004-12-08 CN CN2004800413704A patent/CN1913923B/zh active Active
- 2004-12-08 DE DE602004031870T patent/DE602004031870D1/de active Active
- 2004-12-08 NZ NZ547983A patent/NZ547983A/en not_active IP Right Cessation
- 2004-12-08 PL PL04806560T patent/PL1694361T3/pl unknown
- 2004-12-08 AU AU2004297414A patent/AU2004297414C1/en active Active
- 2004-12-08 JP JP2006543663A patent/JP4332558B2/ja active Active
- 2004-12-08 DK DK04806560.1T patent/DK1694361T3/da active
- 2004-12-08 AT AT04806560T patent/ATE501735T1/de active
- 2004-12-08 EP EP10181873A patent/EP2295084A1/en not_active Withdrawn
-
2007
- 2007-02-22 HK HK07102024.9A patent/HK1095090A1/xx not_active IP Right Cessation
-
2015
- 2015-08-06 US US14/820,464 patent/US9987377B2/en active Active
-
2018
- 2018-06-04 US US15/997,238 patent/US10583200B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2005056749A2 (en) | 2005-06-23 |
EP2295084A1 (en) | 2011-03-16 |
AU2004297414B2 (en) | 2008-10-30 |
ATE501735T1 (de) | 2011-04-15 |
US9987377B2 (en) | 2018-06-05 |
AU2004297414A1 (en) | 2005-06-23 |
EP1694361B1 (en) | 2011-03-16 |
DK1694361T3 (da) | 2011-06-06 |
US10583200B2 (en) | 2020-03-10 |
US20070237744A1 (en) | 2007-10-11 |
CN101954095B (zh) | 2013-03-13 |
WO2005056749A3 (en) | 2005-10-13 |
CN101954095A (zh) | 2011-01-26 |
CA2549840C (en) | 2012-03-20 |
DE602004031870D1 (de) | 2011-04-28 |
US9169495B2 (en) | 2015-10-27 |
PT1694361E (pt) | 2011-06-27 |
AU2004297414C1 (en) | 2009-06-25 |
ES2362881T3 (es) | 2011-07-14 |
CA2549840A1 (en) | 2005-06-23 |
JP4332558B2 (ja) | 2009-09-16 |
US20150343092A1 (en) | 2015-12-03 |
JP2007534310A (ja) | 2007-11-29 |
EP1694361A4 (en) | 2006-12-13 |
CN1913923A (zh) | 2007-02-14 |
PL1694361T3 (pl) | 2011-08-31 |
EP1694361A2 (en) | 2006-08-30 |
NZ547983A (en) | 2009-05-31 |
CN1913923B (zh) | 2010-12-08 |
US20180369416A1 (en) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1095090A1 (en) | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells | |
IL207446A0 (en) | Acid alpha-glucosidase and fragments thereof | |
BR0316525A (pt) | Genes de fosfotransferase de neomicina e processos para seleção de células recombinantes de alta produtividade | |
WO2008012695A3 (en) | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells | |
SG135175A1 (en) | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells | |
WO2005117991A3 (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
CN105646719A (zh) | 一种高效定点转基因的工具及其应用 | |
EP1766035A4 (en) | INTERFERING RNA ENCAPSULATED IN LIPIDS | |
EP1709194A4 (en) | ADMINISTRATION OF DNA OR RNA THROUGH LACUNAR JUNCTION OF HOST CELLS TO TARGET CELLS AND CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR ARNS | |
EP2330200A3 (en) | Gene expression technique | |
ATE222289T1 (de) | Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte | |
AR069253A1 (es) | Plantas transgenicas que expresan el acido nucleico de ossik1 y moduladores para aumentar la tolerancia a estres | |
DE69928556D1 (de) | Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen | |
WO2007044627A3 (en) | Compositions and methods for delivery of interfering rna | |
AU2003294397A1 (en) | Promoter variants for expressing genes in a fungal cell | |
Grant et al. | Sequence-specific alkylation and cleavage of DNA mediated by purine motif triple helix formation | |
EP1458240A4 (en) | NUCLEIC ACIDIC PRODUCTS SUITABLE FOR GLUCOSE-GENERATED PRODUCTION OF HUMAN INSULIN IN SOMATIC CELL LINES | |
JP2024500858A (ja) | 細胞中のhla-aを低減するための組成物及び方法 | |
MXPA05005120A (es) | Secuencias de adn de la region genomica tcd de photorhabdus luminescens. | |
WO2006091233A3 (en) | Cellular delivery of reagents that inhibit gene expression utilizing the anthrax toxin protective antigen (pa) | |
AU2294102A (en) | Mutant muscle-specific enhancers | |
WO2003000894A9 (fr) | Vaccins polynucleotides | |
Maassen et al. | Comparison by photoaffinity labeling of the proteins involved in GTP hydrolysis from 70S ribosomes and a 5S RNA-protein complex from bacillus stearothermophilus | |
MX2023009850A (es) | Composiciones y metodos para la administracion de acidos nucleicos. | |
SG164274A1 (en) | Rapid creation of gene targeting vectors using homologous recombination in yeast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20201206 |